Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
| Autor: | Diana I. Albu, Mary Woodall-Jappe, Natalie C. Twine, Xingfeng Bao, Kuan-Chun Huang, Jiayi Wu, Kenichi Nomoto |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pharmacology
Antitumor activity Cancer Research business.industry Effector Immune checkpoint inhibitors medicine.medical_treatment Immunology Antagonist Cancer Bioinformatics medicine.disease Immune checkpoint Oncology Cancer immunotherapy Poster Presentation Cancer research Molecular Medicine Immunology and Allergy Medicine business Receptor |
| Zdroj: | Journal for Immunotherapy of Cancer |
| ISSN: | 2051-1426 |
| DOI: | 10.1186/2051-1426-3-s2-p350 |
| Popis: | Meeting abstracts Immunotherapies targeting the immune checkpoint receptors have shown great promise for a subset of cancer patients. However, robust and safe combination therapies are still needed to increase the benefit of cancer immunotherapy and bring it to broader patient populations. We have |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink